Float Short %

13.96

Margin Of Safety %

Put/Call OI Ratio

0.18

EPS Next Q Diff

-2.94

EPS Last/This Y

0.77

EPS This/Next Y

-11.2

Price

17.18

Target Price

Analyst Recom

2.33

Performance Q

-7.86

Relative Volume

0.5

Beta

0.21

Ticker: MCRB

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-10	MCRB	14.04	0.12	0.00	12912
2025-11-11	MCRB	14.77	0.12	0.28	13141
2025-11-12	MCRB	16.24	0.12	0.02	13245
2025-11-13	MCRB	16.85	0.13	0.00	13304
2025-11-14	MCRB	16.74	0.13	0.00	13314
2025-11-17	MCRB	21.46	0.13	0.00	13356
2025-11-18	MCRB	24.76	0.12	0.12	13864
2025-11-19	MCRB	28.63	0.13	0.16	13798
2025-11-20	MCRB	21.98	0.16	0.27	13908
2025-11-21	MCRB	17.67	0.17	0.06	15505
2025-11-24	MCRB	16.9	0.16	0.03	12063
2025-11-25	MCRB	16.86	0.16	0.08	12090
2025-11-26	MCRB	16.89	0.16	0.01	12099
2025-12-01	MCRB	17.21	0.18	0.02	12461
2025-12-02	MCRB	16.63	0.18	0.00	12470
2025-12-03	MCRB	17.37	0.18	0.19	12490
2025-12-04	MCRB	17.79	0.18	2.88	12534
2025-12-05	MCRB	16.54	0.18	0.09	12541
2025-12-08	MCRB	17.23	0.18	0.13	12598
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-10	MCRB	14.05	38.2	-	1.34
2025-11-11	MCRB	14.90	38.2	-	1.34
2025-11-12	MCRB	16.23	38.2	-	1.34
2025-11-13	MCRB	16.72	38.2	-	1.34
2025-11-14	MCRB	16.64	38.2	-	1.34
2025-11-17	MCRB	21.53	38.2	-	1.34
2025-11-18	MCRB	24.80	38.2	-	1.34
2025-11-19	MCRB	28.63	38.2	-	1.34
2025-11-20	MCRB	21.80	38.2	-	1.34
2025-11-21	MCRB	17.59	27.3	-	0.77
2025-11-24	MCRB	16.97	27.3	-	0.77
2025-11-25	MCRB	16.92	27.3	-	0.77
2025-11-26	MCRB	16.92	27.3	-	0.77
2025-12-01	MCRB	17.49	27.3	-	0.77
2025-12-02	MCRB	16.70	27.3	-	0.77
2025-12-03	MCRB	17.44	27.3	-	0.77
2025-12-04	MCRB	17.61	27.3	-	0.77
2025-12-05	MCRB	16.66	27.3	-	0.77
2025-12-08	MCRB	17.18	27.3	-	0.77
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-11-10	MCRB	-0.04	-10.08	12.10
2025-11-11	MCRB	-0.04	-10.08	12.10
2025-11-12	MCRB	-0.04	-10.08	14.92
2025-11-13	MCRB	-0.04	-10.08	14.92
2025-11-14	MCRB	-0.04	-10.08	14.83
2025-11-17	MCRB	-0.04	-9.61	14.83
2025-11-18	MCRB	-0.14	-9.61	14.83
2025-11-19	MCRB	-0.14	-9.61	14.83
2025-11-20	MCRB	-0.12	-9.61	14.83
2025-11-21	MCRB	-0.12	-9.61	14.83
2025-11-24	MCRB	-0.12	-1.91	14.85
2025-11-25	MCRB	-0.12	-1.91	14.85
2025-11-26	MCRB	-0.12	-1.91	13.96
2025-12-01	MCRB	-0.12	-1.78	13.96
2025-12-02	MCRB	-0.12	-1.78	13.96
2025-12-03	MCRB	-0.12	-1.78	13.96
2025-12-04	MCRB	-0.12	-1.78	13.96
2025-12-05	MCRB	-0.12	-1.78	13.96
2025-12-08	MCRB	-0.12	-1.75	13.96
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

0.94

Avg. EPS Est. Current Quarter

-1.6

Avg. EPS Est. Next Quarter

-2

Insider Transactions

-0.12

Institutional Transactions

-1.75

Beta

0.21

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

97.1

Max Drawdown 5-Year %

-98.8

Target Price

P/E

28.3

Forward P/E

PEG

P/S

444.04

P/B

3.45

P/Free Cash Flow

EPS

0.61

Average EPS Est. Cur. Y

0.77

EPS Next Y. (Est.)

-10.43

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

1536.75

Relative Volume

0.5

Return on Equity vs Sector %

-14.5

Return on Equity vs Industry %

0.4

EPS 1 7Days Diff

-0.6

EPS 1 30Days Diff

-0.57

EBIT Estimation

Seres Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 103

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline programs include SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease; and SER-287 and SER-301, which are in clinical trials for the treatment of mild-to-moderate ulcerative colitis. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

stock quote shares MCRB – Seres Therapeutics, Inc. Stock Price stock today

news today MCRB – Seres Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch MCRB – Seres Therapeutics, Inc. yahoo finance google finance

stock history MCRB – Seres Therapeutics, Inc. invest stock market

stock prices MCRB premarket after hours

ticker MCRB fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: MCRB

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y